Online inquiry

IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1467MR)

This product GTTS-WQ1467MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1467MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12827MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ175MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ3348MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ3159MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AR-101
GTTS-WQ330MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 1F5
GTTS-WQ10503MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ11145MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MDX-1103
GTTS-WQ11463MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEHD7945A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW